Cite

    Bruzzese, A. et al. (2022). Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials. Hematological oncology. 40 (4), pp. 704-715. [Online].